A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors
ConclusionsThe MTD/RPTD of GD is gemcitabine 1000 mg/m2 weekly for 3 of 4 weeks and dasatinib 50 mg PO BID. The clinical activity of GD seen in this study was modest, and does not support its further investigation in pancreatic cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Anemia | Bilirubin | Cancer | Cancer & Oncology | Chemotherapy | Dermatology | Drugs & Pharmacology | Erbitux | Pancreas | Pancreatic Cancer | Skin | Skin Biopsy | Study | Thrombocytopenia | Toxicology